Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Watanabe T et al. – Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T–cell lymphoma (CTCL). A phase I trial of oral vorinostat was conducted in Japanese patients with malignant lymphoma. The data suggest that further investigations of vorinostat in non–Hodgkin lymphoma, focusing on FL and MCL, are warranted.

Related Articles

A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer
Clinical Cancer Research, 11/06/09    Relevance Score: 85%

Molecular Targets in Malignant Pleural Mesothelioma Treatment
Current Drug Targets, 11/10/09    Relevance Score: 80%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address